AMGN vs CAH: fair value comparison
Amgen Inc. and Cardinal Health, Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMGN currently sits closer to the top of our discount ranking. AMGN carries the stronger quality grade.
| AMGN | CAH | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $377.35 | $234.57 |
| 12-month range | $294.20–$438.12 | $190.22–$239.35 |
| Sector rank | #92 of 113 Healthcare | #97 of 113 Healthcare |
| Quality grade | B | F |
| Leverage | High | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: AMGN fair value analysis · CAH fair value analysis